However, both genetic targeting (Figure 3(a)) and pharmacological inhibition of ACKR2 with an anti-ACKR2 antibody (Figure 3(b)) significantly reduced B16-F10 tumor growth. The gene discussed is ACKR2; the disease is neoplasm.